EBGLYSS Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (12 years and older with a body weight of at least 40 kg) who are candidates for systemic therapy.
The European Commission (EC) is now reviewing the positive CHMP opinion. This biologic is expected to be approved in the European Union within two months, and it might be launched in the first ...
